Merrimack stock: buy or sell?
September 20th, 2019
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States.
Should I buy Merrimack stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading strategy that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Merrimack Pharmaceuticals stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Merrimack stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for MACK stock for the last month.
Merrimack stock analysis
Merrimack shares skyrocketed 4.66% to $5.84 today.
Merrimack shares skyrocketed 4.66% to $5.84 today. Since price and SMA200d lines crossed up on July, MACK climbed $2.75 (89.00%). MACK is retaking the upward trend marking a new rising bottom heading to break out over $6.19. For the last 25 days when SMA50d and SMA100d crossed up, MACK price gained $1.98 per share (51.30%).
Shares of Merrimack Pharmaceuticals climbed an exceptional 6.76% this week. Late August MACK plummed a bloodcurdling -7.52% in just one week.
Merrimack stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, MACK might consolidate in a flat-base, waiting to break out over or down under . Since price and SMA40w lines crossed up late July, MACK climbed $2.77 (90.23%). Since late March when SMA20w and SMA40w crossed up, MACK price gained $2.01 per share (52.48%).
Merrimack stock price history
Merrimack stock went public on March 29th, 2012 with a price of $24.361. Since then, MACK stock declined a -76.00%, with a yearly average of -10.90%.
1: Adjusted price after possible price splits or reverse-splits.
Merrimack stock historical price chart
MACK stock reached 52-week highs on September 12th at $6.19, and all-time highs 2015-04-27 with a price of 53.94.
Merrimack stock price targetPredicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not found any price forecast for Merrimack stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Merrimack Pharmaceuticals didn't meet the expectations of the experts and reported a bad EPS of $-0.97 per share when experts were expecting $-1.01.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2016, Merrimack Pharmaceuticals annual sales rocketed a dazzling 61.64% to $144.27 M USD from $89.26 marked in 2015. When comparing 2016 vs 2015, likewise, profit margin (that is, the net income divided by revenues) skyrocketed a 60.59% to -105.18%.
|2013||$48 M||-||$-130.93 M-274.0%||-|
|2014||$103 M||115.02%||$-83.29 M-81.1%||-36.39%|
|2015||$89 M||-13.14%||$-147.96 M-165.8%||77.64%|
|2016||$144 M||61.64%||$-151.74 M-105.2%||2.56%|
Quarterly financial resultsReported quarter earnings marked $-8.94 M with a profit margin of . Profit margin remained stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Merrimack Pharmaceuticals sales marked a tight movement and remained stable a nan%. Looking back to recent quarterly results, Merrimack Pharmaceuticals posted 7 negative quarters in a row.
Merrimack ownershipWhen you are planning to buy shares of a company, it's always worth to have a look its ownership structure.
Merrimack Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 4.09% of all shares.
In case of Merrimack Pharmaceuticals stock, 57.26% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for MACK stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Merrimack:
|Market cap||$78.0 M||$154.3 M||$70.4 B||$259.1 M||$14.2 M|
|Total shares||13.4 M||160.7 M||708.7 M||54.7 M||16.7 M|
|Float shares||9.1 M||134.8 M||706.3 M||43.0 M||13.9 M|
|- Institutional holdings (%)||57.3%||32.5%||77.6%||103.6%||8.1%|
|- Insider holdings (%)||4.1%||0.3%||0.2%||3.0%||16.9%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$5.50 - $5.87|
|Average true range||$0.49|
|50d mov avg||$4.01|
|100d mov avg||$3.69|
|200d mov avg||$3.45|
Merrimack performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We picked AVEO Pharmaceuticals, Celgene, Clovis Oncology, Dare Bioscience, Geron, Immunomedics, Madrigal Pharmaceuticals and as the bechmarking frame for Merrimack stock.